Davids MS, Ryan CE, Lampson BL, Ren Y, et al. Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease. J Clin Oncol 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503.
PMID: 39645236